Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00665457 · ClinicalTrials.gov registry record · Phase 2
Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery
A Phase 2 study, sponsored by University of Nebraska.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT00665457 is a Phase 2 study that was terminated before completion, run by University of Nebraska. The registered enrollment target is 3 participants.
The verdict
NCT00665457, a Phase 2 study, was terminated before completion, sponsored by University of Nebraska.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
RATIONALE: Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This phase II clinical trial is studying biomarkers and side effects in women receiving chemotherapy and celecoxib for stage II or stage III breast cancer that can be removed by surgery.
Interventions
- DRUG cyclophosphamide
- DRUG docetaxel
- DRUG capecitabine
- BIOLOGICAL filgrastim
- DRUG celecoxib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2004-04-15 |
| Est. Completion | 2009-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00665457
The ClinicalTrials.gov registry entry for NCT00665457 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00665457 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00665457 about?
NCT00665457 is a clinical study titled "Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery". RATIONALE: Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This phase II clinical trial is studying biomarkers and side effects in women receiving c...
What is the current status of trial NCT00665457?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2004-04-15. Estimated completion is 2009-07-31.
What interventions are being tested in trial NCT00665457?
The interventions under investigation include: cyclophosphamide (DRUG), docetaxel (DRUG), capecitabine (DRUG), filgrastim (BIOLOGICAL), celecoxib (DRUG).
Who is sponsoring clinical trial NCT00665457?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.